Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)
China · Delayed Price · Currency is CNY 13.70
+0.48 (3.63%)
Apr 30, 2026, 3:04 PM CST
SHE:002365 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 778.29 | 833.34 | 959.37 | 1,426 | 1,546 |
Other Revenue | 4.88 | 5.47 | 13.52 | 36.57 | 19.54 |
| 783.17 | 838.81 | 972.89 | 1,462 | 1,565 | |
Revenue Growth (YoY) | -6.63% | -13.78% | -33.48% | -6.58% | 33.47% |
Cost of Revenue | 652.09 | 672.79 | 722.37 | 991.13 | 1,212 |
Gross Profit | 131.08 | 166.02 | 250.52 | 471.32 | 353.73 |
Selling, General & Admin | 98.64 | 80.61 | 176.42 | 249.77 | 154.58 |
Research & Development | 30.88 | 36.97 | 41.5 | 40.45 | 53.04 |
Other Operating Expenses | 9.9 | 9.16 | 10.09 | 13.66 | 11.58 |
Operating Expenses | 139.33 | 126.05 | 226.39 | 301.41 | 228.94 |
Operating Income | -8.25 | 39.97 | 24.12 | 169.91 | 124.79 |
Interest Expense | -0.94 | -0.59 | -0.37 | -0.66 | -2.44 |
Interest & Investment Income | 31.92 | 40.78 | 27.39 | 12.62 | 24.2 |
Currency Exchange Gain (Loss) | -0.13 | 9.17 | 5.64 | 21.55 | -4.09 |
Other Non Operating Income (Expenses) | -0.88 | -1.02 | -0.43 | -0.64 | -0.7 |
EBT Excluding Unusual Items | 21.71 | 88.32 | 56.35 | 202.77 | 141.76 |
Impairment of Goodwill | - | -0.52 | -8.25 | - | - |
Gain (Loss) on Sale of Investments | -1.09 | 4.43 | -34.55 | -30.34 | -0.28 |
Gain (Loss) on Sale of Assets | 0.19 | -0.33 | 45.02 | -0.38 | 0.25 |
Asset Writedown | -14.66 | -15.36 | -42.06 | -3.65 | -3.02 |
Legal Settlements | -1.13 | -10.02 | -23.3 | -22.73 | -13.61 |
Other Unusual Items | 4.84 | 4.33 | 12.84 | 7.4 | 4.75 |
Pretax Income | 9.88 | 70.86 | 6.05 | 153.06 | 129.85 |
Income Tax Expense | 2.69 | 11.15 | 34.47 | 20.34 | 10.81 |
Earnings From Continuing Operations | 7.19 | 59.71 | -28.41 | 132.72 | 119.05 |
Minority Interest in Earnings | 15.3 | 2.06 | 16.1 | 7.63 | -7.63 |
Net Income | 22.49 | 61.77 | -12.31 | 140.35 | 111.42 |
Preferred Dividends & Other Adjustments | - | - | - | 0.19 | 3.63 |
Net Income to Common | 22.49 | 61.77 | -12.31 | 140.16 | 107.78 |
Net Income Growth | -63.58% | - | - | 25.97% | 5.55% |
Shares Outstanding (Basic) | 289 | 293 | 295 | 294 | 287 |
Shares Outstanding (Diluted) | 289 | 295 | 295 | 294 | 287 |
Shares Change (YoY) | -1.82% | - | 0.13% | 2.66% | -0.63% |
EPS (Basic) | 0.08 | 0.21 | -0.04 | 0.48 | 0.38 |
EPS (Diluted) | 0.08 | 0.21 | -0.04 | 0.48 | 0.38 |
EPS Growth | -62.93% | - | - | 26.66% | 2.75% |
Free Cash Flow | 76.81 | -12.33 | 100.46 | 238.21 | 38.76 |
Free Cash Flow Per Share | 0.27 | -0.04 | 0.34 | 0.81 | 0.14 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | - |
Gross Margin | 16.74% | 19.79% | 25.75% | 32.23% | 22.60% |
Operating Margin | -1.05% | 4.76% | 2.48% | 11.62% | 7.97% |
Profit Margin | 2.87% | 7.36% | -1.27% | 9.58% | 6.88% |
Free Cash Flow Margin | 9.81% | -1.47% | 10.32% | 16.29% | 2.48% |
EBITDA | 108.42 | 152.8 | 159.3 | 293.53 | 240.75 |
EBITDA Margin | 13.84% | 18.22% | 16.37% | 20.07% | 15.38% |
D&A For EBITDA | 116.68 | 112.83 | 135.18 | 123.62 | 115.96 |
EBIT | -8.25 | 39.97 | 24.12 | 169.91 | 124.79 |
EBIT Margin | -1.05% | 4.76% | 2.48% | 11.62% | 7.97% |
Effective Tax Rate | 27.21% | 15.74% | 569.54% | 13.29% | 8.32% |
Revenue as Reported | 783.17 | 838.81 | 972.89 | 1,462 | 1,565 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.